{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:25:41Z","timestamp":1778797541555,"version":"3.51.4"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Cystic Fibrosis (CF) results from over 400 different disease-causing mutations in the CF Transmembrane Conductance Regulator (<jats:italic>CFTR<\/jats:italic>) gene. These <jats:italic>CFTR<\/jats:italic> mutations lead to numerous defects in CFTR protein function. A novel class of targeted therapies (CFTR modulators) have been developed that can restore defects in CFTR folding and gating. This study aimed to characterize the functional and structural defects of S945L-CFTR and interrogate the efficacy of modulators with two modes of action: gating potentiator [ivacaftor (IVA)] and folding corrector [tezacaftor (TEZ)]. The response to these modulators <jats:italic>in vitro<\/jats:italic> in airway differentiated cell models created from a participant with S945L\/G542X-CFTR was correlated with <jats:italic>in vivo<\/jats:italic> clinical outcomes of that participant at least 12 months pre and post modulator therapy. In this participants' airway cell models, CFTR-mediated chloride transport was assessed <jats:italic>via<\/jats:italic> ion transport electrophysiology. Monotherapy with IVA or TEZ increased CFTR activity, albeit not reaching statistical significance. Combination therapy with TEZ\/IVA significantly (<jats:italic>p\u2009<\/jats:italic>=\u20090.02) increased CFTR activity 1.62-fold above baseline. Assessment of CFTR expression and maturation <jats:italic>via<\/jats:italic> western blot validated the presence of mature, fully glycosylated CFTR, which increased 4.1-fold in TEZ\/IVA-treated cells. The <jats:italic>in vitro<\/jats:italic> S945L-CFTR response to modulator correlated with an improvement in <jats:italic>in vivo<\/jats:italic> lung function (ppFEV<jats:sub>1<\/jats:sub>) from 77.19 in the 12 months pre TEZ\/IVA to 80.79 in the 12 months post TEZ\/IVA. The slope of decline in ppFEV1 significantly (<jats:italic>p\u2009<\/jats:italic>=\u20090.02) changed in the 24 months post TEZ\/IVA, becoming positive. Furthermore, there was a significant improvement in clinical parameters and a fall in sweat chloride from 68 to 28\u2005mmol\/L. The mechanism of dysfunction of S945L-CFTR was elucidated by <jats:italic>in silico<\/jats:italic> molecular dynamics (MD) simulations. S945L-CFTR caused misfolding of transmembrane helix 8 and disruption of the R domain, a CFTR domain critical to channel gating. This study showed <jats:italic>in vitro<\/jats:italic> and <jats:italic>in silico<\/jats:italic> that S945L causes both folding and gating defects in CFTR and demonstrated <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> that TEZ\/IVA is an efficacious modulator combination to address these defects. As such, we support the utility of patient-derived cell models and MD simulations in predicting and understanding the effect of modulators on CFTR function on an individualized basis.<\/jats:p>","DOI":"10.3389\/fped.2022.1062766","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T06:24:05Z","timestamp":1668579845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["S945L-CFTR molecular dynamics, functional characterization and tezacaftor\/ivacaftor efficacy in vivo and in vitro in matched pediatric patient-derived cell models"],"prefix":"10.3389","volume":"10","author":[{"given":"Katelin M.","family":"Allan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miro A.","family":"Astore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura K.","family":"Fawcett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Chia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Kuyucak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafagh A.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic Fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1073\/pnas.1815287115","article-title":"Molecular structure of the atp-bound, phosphorylated human Cftr","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1085\/jgp.200409174","article-title":"Functional roles of nonconserved structural segments in cftr's Nh2-terminal nucleotide binding domain","volume":"125","author":"Csanady","year":"2005","journal-title":"J Gen Physiol"},{"key":"B5","year":""},{"key":"B6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.E14-04-0935","article-title":"From cftr biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.gene.2014.02.040","article-title":"Cftr genotype and clinical outcomes of adult patients carried as cystic fibrosis disease","volume":"540","author":"Bonadia","year":"2014","journal-title":"Gene"},{"key":"B9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1172\/JCI35138","article-title":"Gene modifiers in cystic fibrosis","volume":"118","author":"Accurso","year":"2008","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1008007","DOI":"10.1371\/journal.pgen.1008007","article-title":"Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci","volume":"15","author":"Gong","year":"2019","journal-title":"PLoS Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jcf.2022.02.007","article-title":"Expression of cystic fibrosis lung disease modifier genes in human airway models","volume":"21","author":"He","year":"2022","journal-title":"J Cyst Fibros"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"Cftr modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of cf airway epithelial cell function in vitro by a cftr potentiator, vx-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple cftr channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J Cyst Fibros"},{"key":"B15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1183\/13993003.01192-2015","article-title":"Optimal correction of distinct cftr folding mutants in rectal cystic fibrosis organoids","volume":"48","author":"Dekkers","year":"2016","journal-title":"Eur Respir J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1159\/000475578","article-title":"Combination of correctors rescues cftr transmembrane-domain mutants by mitigating their interactions with proteostasis","volume":"41","author":"Lopes-Pacheco","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del cftr","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3389\/fphar.2018.01429","article-title":"Human primary epithelial cell models: promising tools in the era of cystic fibrosis personalized medicine","volume":"9","author":"Awatade","year":"2018","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of fda and ema regulatory decision-making process on the access to cftr modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1656","DOI":"10.1002\/mgg3.1656","article-title":"Ex vivo model predicted in vivo efficacy of cftr modulator therapy in a child with rare genotype","volume":"9","author":"Terlizzi","year":"2021","journal-title":"Mol Genet Genomic Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ppul.23659","article-title":"In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual cftr function: n-of-1 studies","volume":"52","author":"McGarry","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jcf.2016.09.005","article-title":"Therapeutic benefit observed with the cftr potentiator, ivacaftor, in a cf patient homozygous for the W1282x cftr nonsense mutation","volume":"16","author":"Mutyam","year":"2017","journal-title":"J Cyst Fibros"},{"key":"B25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jcf.2020.07.003","article-title":"Cftr modulator therapy for cystic fibrosis caused by the rare C.3700a\u2009>\u2009G mutation","volume":"20","author":"Phuan","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1702457","DOI":"10.1183\/13993003.02457-2017","article-title":"Personalised cftr pharmacotherapeutic response testing and therapy of cystic fibrosis","volume":"51","author":"McCarthy","year":"2018","journal-title":"Eur Respir J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/jpm12040632","article-title":"Theratyping of the rare cftr variants E193k and R334w in rectal organoid-derived epithelial monolayers","volume":"12","author":"Ciciriello","year":"2022","journal-title":"J Pers Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to cftr-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1165\/rcmb.2021-0337OC","article-title":"Molecular dynamics and theratyping in airway and gut organoids reveal R352q-cftr conductance defect","volume":"67","author":"Wong","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103710","DOI":"10.1016\/j.isci.2021.103710","article-title":"Molecular dynamics and functional characterization of I37r-cftr lasso mutation provide insights into channel gating activity","volume":"25","author":"Wong","year":"2022","journal-title":"iScience"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100598","DOI":"10.1016\/j.jbc.2021.100598","article-title":"The cftr P67l variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue","volume":"296","author":"Sabusap","year":"2021","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fphar.2020.00295","article-title":"Functional and pharmacological characterization of the rare cftr mutation W361r","volume":"11","author":"Billet","year":"2020","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00018-019-03043-2","article-title":"Contribution of the eighth transmembrane segment to the function of the cftr chloride channel pore","volume":"76","author":"Negoda","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.aaw7611","article-title":"Structural identification of a hotspot on cftr for potentiation","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on cftr forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"key":"B37","year":""},{"key":"B38","doi-asserted-by":"publisher","first-page":"27493","DOI":"10.1074\/jbc.271.44.27493","article-title":"Cytoplasmic loop three of cystic fibrosis transmembrane conductance regulator contributes to regulation of chloride channel activity","volume":"271","author":"Seibert","year":"1996","journal-title":"J Biol Chem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","article-title":"Influence of cell background on pharmacological rescue of mutant cftr","volume":"298","author":"Pedemonte","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.bpj.2018.03.003","article-title":"Structure of transmembrane Helix 8 and possible membrane defects in cftr","volume":"114","author":"Corradi","year":"2018","journal-title":"Biophys J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/hmg\/1.7.542","article-title":"Cftr nonsense mutations G542x and W1282x associated with severe reduction of cftr mrna in nasal epithelial cells","volume":"1","author":"Hamosh","year":"1992","journal-title":"Hum Mol Genet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B43","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of cftr modulators for the treatment of cystic fibrosis","volume":"16","author":"Lopes-Pacheco","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e63090","DOI":"10.3791\/63090","article-title":"Collection, expansion, and differentiation of primary human nasal epithelial cell models for quantification of cilia beat frequency","volume":"177","author":"Allan","year":"2021","journal-title":"J Vis Exp"},{"key":"B45","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"Rock inhibitor and feeder cells induce the conditional reprogramming of epithelial cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am J Pathol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"20035","DOI":"10.1073\/pnas.1213241109","article-title":"Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells","volume":"109","author":"Suprynowicz","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B47","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jcf.2020.12.019","article-title":"Significant functional differences in differentiated conditionally reprogrammed (crc)- and feeder-free dual smad inhibited-expanded human nasal epithelial cells","volume":"20","author":"Awatade","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B48","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nature15729","article-title":"F508 cftr interactome remodelling promotes rescue of cystic fibrosis","volume":"528","author":"Pankow","year":"2015","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"B50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"Charmm36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat Methods"},{"key":"B51","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/(SICI)1096-987X(199906)20:8786::AID-JCC5%3E3.0.CO;2-B","article-title":"Improving efficiency of large time-scale molecular dynamics simulations of hydrogen-rich systems","volume":"20","author":"Feenstra","year":"1999","journal-title":"J Comput Chem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/jcc.26198","article-title":"Mkvsites: a tool for creating gromacs virtual sites parameters to increase performance in all-atom molecular dynamics simulations","volume":"41","author":"Larsson","year":"2020","journal-title":"J Comput Chem"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1021\/acs.jctc.8b00267","article-title":"Faster simulations with a 5\u2005fs time step for lipids in the charmm force field","volume":"14","author":"Olesen","year":"2018","journal-title":"J Chem Theory Comput"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.cpc.2009.05.011","article-title":"Plumed: a portable plugin for free-energy calculations with molecular dynamics","volume":"180","author":"Bonomi","year":"2009","journal-title":"Comput Phys Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.cpc.2013.09.018","article-title":"Plumed 2: new feathers for an old bird","volume":"185","author":"Tribello","year":"2014","journal-title":"Comput Phys Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41592-019-0506-8","article-title":"Promoting transparency and reproducibility in enhanced molecular simulations","volume":"16","author":"consortium","year":"2019","journal-title":"Nat Methods"},{"key":"B57","author":"Grossfield","year":""},{"key":"B58","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"B59","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-cftr protein processing defect in vitro by the investigational drug vx-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare cftr mutants by elexacaftor-tezacaftor-ivacaftor (trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1021\/acs.jcim.0c01207","article-title":"Stability prediction for mutations in the cytosolic domains of cystic fibrosis transmembrane conductance regulator","volume":"61","author":"Bahia","year":"2021","journal-title":"J Chem Inf Model"},{"key":"B62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jcf.2017.12.005","article-title":"Ivacaftor restores cftr-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945l alleles","volume":"17","author":"Kim","year":"2018","journal-title":"J Cyst Fibros"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"Vx-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jcf.2018.05.010","article-title":"Combination potentiator (\u2018co-potentiator\u2019) therapy for cf caused by cftr mutants, including N1303k, that are poorly responsive to single potentiators","volume":"17","author":"Phuan","year":"2018","journal-title":"J Cyst Fibros"},{"key":"B66","doi-asserted-by":"publisher","first-page":"17640","DOI":"10.1038\/s41598-019-54158-2","article-title":"Nanomolar-Potency \u2018co-potentiator\u2019 therapy for cystic fibrosis caused by a defined subset of minimal function cftr mutants","volume":"9","author":"Phuan","year":"2019","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/biom11101417","article-title":"Nbd2 is required for the rescue of mutant F508del cftr by a thiazole-based molecule: a class ii corrector for the multi-drug therapy of cystic fibrosis","volume":"11","author":"Brandas","year":"2021","journal-title":"Biomolecules"},{"key":"B68","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jcf.2019.04.014","article-title":"Cftr activity is enhanced by the novel corrector Glpg2222, given with and without ivacaftor in two randomized trials","volume":"18","author":"Bell","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jcf.2020.07.015","article-title":"Emerging preclinical modulators developed for F508del-cftr have the potential to be effective for orkambi resistant processing mutants","volume":"20","author":"Laselva","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B70","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov"},{"key":"B71","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00018-022-04215-3","article-title":"Targeting the E1 ubiquitin-activating enzyme (Uba1) improves elexacaftor\/tezacaftor\/ivacaftor efficacy towards F508del and rare misfolded cftr mutants","volume":"79","author":"Borgo","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A cftr corrector (lumacaftor) and a cftr potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a Phe508del cftr mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1062766\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T06:24:07Z","timestamp":1668579847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1062766\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":72,"alternative-id":["10.3389\/fped.2022.1062766"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1062766","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"article-number":"1062766"}}